RNXT Share Price Performance
US$1.21
0.01 (0.83%)
71.2% undervalued intrinsic discount
US$4.20
Fair Value
Price US$1.21
Stock_Research_Today US$4.20
Fair ValueUS$4.20
Share PriceUS$1.21
71.2% undervalued intrinsic discount
RNXT Community Narratives
ST
Fair Value US$4.20 71.2% undervalued intrinsic discount
Revolutionizing Cancer Treatment
15users have liked this narrative
3users have commented on this narrative
121users have followed this narrative
RNXT Community Fair Values
- US$4.20FV71.2% undervalued intrinsic discount371.30%Revenue growth p.a.15users have liked this narrative3users have commented on this narrative121users have followed this narrative2 months ago author updated this narrative
Recent RNXT News & Updates
No updates
RenovoRx, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
Aug 14, 2025
- Earnings per share (EPS)
- -0.28
- Gross Margin
- 60.83%
- Net Profit Margin
- -4,232.50%
- Debt/Equity Ratio
- 0%
RenovoRx, Inc. Competitors
About RNXT
- Founded
- 2009
- Employees
- 10
- CEO
- WebsiteView website
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Mountain View, California.
U.S. Market Performance
- 7 Days: -1.2%
- 3 Months: 13.1%
- 1 Year: 22.8%
- Year to Date: 7.3%
Over the last 7 days, the market has dropped 1.2%, driven by a decline of 4.7% in the Consumer Discretionary sector. In contrast to the last week, the market is actually up 23% over the past year. Earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading